Literature DB >> 85001

Rapid emergence of El Tor Vibrio cholerae resistant to antimicrobial agents during first six months of fourth cholera epidemic in Tanzania.

F S Mhalu, P W Mmari, J Ijumba.   

Abstract

110 El Tor Vibrio cholerae isolates from 102 patients with cholera between November, 1977, and March, 1978, during the early stages of the fourth epidemic of cholera in Tanzania had minimum inhibitory concentrations to tetracycline, chloramphenicol, nitrofurantoin, neomycin, ampicillin, and sulphadimidine determined. All isolates during the first month after the disease was recognised were fully sensitive to tetracycline, but 76% of isolates were resistant to the drug after five months of extensive use of tetracycline therapeutically and prophylactically in the country. Resistance to the five other antibacterial agents developed more slowly. Isolates from patients who failed to clear the organism from their stools or who had cholera soon after tetracycline prophylaxis had increased minimum inhibitory concentrations of the drug. Resistance did not develop in vivo. Although resistance to tetracycline readily developed following extensive use of the drug, such a resistance was not the only reason for failure of tetracycline treatment and prophylaxis. Mass chemoprophylaxis in the control of cholera should be discouraged unless evidence to the contrary becomes available.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 85001     DOI: 10.1016/s0140-6736(79)92889-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  32 in total

1.  Antibiotic resistance conferred by a conjugative plasmid and a class I integron in Vibrio cholerae O1 El Tor strains isolated in Albania and Italy.

Authors:  V Falbo; A Carattoli; F Tosini; C Pezzella; A M Dionisi; I Luzzi
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

2.  Transmission modes and the evolution of virulence : With special reference to cholera, influenza, and AIDS.

Authors:  P W Ewald
Journal:  Hum Nat       Date:  1991-03

3.  Antimicrobial Resistance Risks of Cholera Prophylaxis for United Nations Peacekeepers.

Authors:  Amber Kunkel; Joseph A Lewnard; Virginia E Pitzer; Ted Cohen
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

4.  Differences in antimicrobial susceptibilities of clinical isolates in Saudi Arabia and the United States.

Authors:  S M Qadri; S Ostrawski; S Johnson; D J Flournoy
Journal:  J Natl Med Assoc       Date:  1987-04       Impact factor: 1.798

5.  The early stage of the recurrent cholera epidemic in Luanda, Angola.

Authors:  M M Colombo; M Francisco; B D Ferreira; S Rubino; P Cappuccinelli
Journal:  Eur J Epidemiol       Date:  1993-09       Impact factor: 8.082

Review 6.  [Resistance to antimicrobial agents. A WHO Scientific Working Group].

Authors: 
Journal:  Bull World Health Organ       Date:  1983       Impact factor: 9.408

7.  Vitek system antimicrobial susceptibility testing of O1, O139, and non-O1 Vibrio cholerae.

Authors:  C V Sciortino; J A Johnson; A Hamad
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

8.  Emergence and rapid spread of tetracycline-resistant Vibrio cholerae strains, Madagascar.

Authors:  Jacques-Albert Dromigny; Olivat Rakoto-Alson; Davidra Rajaonatahina; René Migliani; Justin Ranjalahy; Philippe Mauclére
Journal:  Emerg Infect Dis       Date:  2002-03       Impact factor: 6.883

9.  Drug response and genetic properties of Vibrio cholerae associated with endemic cholera in north-eastern Thailand, 2003-2011.

Authors:  Chariya Chomvarin; Fatema-Tuz Johura; Shahnewaj B Mannan; Warin Jumroenjit; Boonnapa Kanoktippornchai; Waraluk Tangkanakul; Napaporn Tantisuwichwong; Sriwanna Huttayananont; Haruo Watanabe; Nur A Hasan; Anwar Huq; Alejandro Cravioto; Rita R Colwell; Munirul Alam
Journal:  J Med Microbiol       Date:  2013-01-14       Impact factor: 2.472

10.  Clinical outcomes in household contacts of patients with cholera in Bangladesh.

Authors:  Ana A Weil; Ashraful I Khan; Fahima Chowdhury; Regina C Larocque; A S G Faruque; Edward T Ryan; Stephen B Calderwood; Firdausi Qadri; Jason B Harris
Journal:  Clin Infect Dis       Date:  2009-11-15       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.